Millie
your market intelligence analyst
Search Results
133 results
Your search is now limited to «Celgene» expert search.
IPWatchdog 08/11/2019 12:15
In the Celgene case, the panel actively discouraged safety by making it far easier to find virtually any safety-related invention obvious.
More from IPWatchdog:
Seeking Alpha 08/08/2019 14:07
As the Celgene (CELG) acquisition heads towards closure, investors need to position themselves for owning shares in the new Bristol-Myers Squibb (BMY.
More from Seeking Alpha:
Investor's Business Daily 08/08/2019 08:00
Pharmaceutical company Bristol-Myers Squibb (BMY) kicked off 2019 by announcing a $74 billion plan to buy biotech giant Celgene (CELG.
More from Investor's Business Daily:
Motley Fool 08/06/2019 15:37
The merger is now expected to close at the end of this year or early next year, so we'll probably get at least one more report out of Celgene.
More from Motley Fool:
FiercePharmaManufacturing 08/04/2019 17:21
Celgene plans to lift the importance of brain health in multiple sclerosis—quite literally—with a new hot air balloon.
More from FiercePharmaManufacturing:
PMLiVE 07/31/2019 05:52
Otezla buoyant Meanwhile, Celgene’s other big product – Otezla (apremilast) for psoriasis, psoriatic arthritis and latterly Behçet’s disease – had another spectacular quarter with a 31% gain to $493m, just as Celgene has to find a buyer to settle antitrust concerns as it pushes through its $74bn merger with Bristol-Myers Squibb ...
More from PMLiVE:
Reuters.com 07/30/2019 19:07
The U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) does not violate the Takings Clause of the Fifth Amendment when it invalidates patents that predate the America Invents Act of 2011, a federal appeals court said on Tuesday.
More from Reuters.com:
MedCity News 07/30/2019 16:24
Celgene filing plans potentially mean two more CAR-Ts on the market by end of next year.
More from MedCity News:
Business Wire 07/30/2019 07:30
Outstanding operating performance in the second quarter supports raising our full-year financial guidance,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation.
More from Business Wire:
Benzinga 07/26/2019 13:24
Hach Rose Schirripa & Cheverie filed this class action suit in 2014, alleging that Celgene had monopolized the market for two drugs, Thalomid and Revlimid, which are primarily used to treat multiple myeloma, a cancer that forms in the blood.
More from Benzinga:
Becker's Hospital Review 07/24/2019 16:59
New Jersey-based Celgene will pay $55 million to resolve a class-action suit that accused the drugmaker of blocking generic competition in the cancer market at the expense of patients.
More from Becker's Hospital Review:
ENDPOINTS 07/23/2019 17:18
Celgene’s business team isn’t waiting for the big merger with Bristol-Myers Squibb to go through before syncing its strategy with the new mother ship.
More from ENDPOINTS:
GlobeNewswire 07/23/2019 16:00
Jounce retains full worldwide rights to its pipeline beyond JTX-8064, including vopratelimab, JTX-4014 and all discovery programs, as Jounce and Celgene have also entered into a mutual agreement to terminate their original strategic collaboration agreement.
More from GlobeNewswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications